"We are delighted to get this trial underway with the dosing of the first patient," said Richard Marsden, the chief executive officer of Synairgen
() said it has now commenced dosing patients in its trial of SNG001 (inhaled formulation of interferon-beta-1a) in coronavirus (COVID-19) patients.
The respiratory drug discovery and development company said the first patient has been dosed at the University Hospital Southampton NHS Foundation Trust. Another six trial sites are expected to start dosing in the next few days.
“The team has worked tirelessly and intensively with the relevant authorities and collaborators to get to this stage, and we now look forward to recruiting more patients and completing the trial as soon as possible. A successful outcome from this trial in COVID-19 patients would be a very important step towards a major breakthrough in the fight against this coronavirus pandemic,” Richard Marsden, the chief executive officer of Synairgen said in a statement.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Synairgen PLC named herein, including the promotion by the Company of Synairgen PLC in any Content on the Site, the Company receives from said...
FOR OUR FULL DISCLAIMER CLICK HERE